Floatz logo

Rgx-111

Mucopolysaccharidosis Type 1

REGENXBIO Inc.gene_therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Mucopolysaccharidosis Type 1 cohort.

Asset / SponsorPhaseRating
Aldurazyme
Genzyme, a Sanofi Company
Phase 4A
Iduronidase, .Alpha.-L-(8-Histidine) (Human)
University of California, San Francisco
Phase 4BBB
Valanafusp Alfa
ArmaGen, Inc
Phase 1/2BB
Rhidu
Genzyme, a Sanofi Company
Phase 3BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 15 →

Same molecule, other indications

Rgx-111 is also rated in:

Hurler syndromeDormant
CCC
Indicative · Phase 1/2
48 / 100
View asset →
Hurler-Scheie syndromeDormant
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →